Granite Investment Partners LLC lifted its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 120.3% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 118,894 shares of the medical device company’s stock after buying an additional 64,922 shares during the period. Granite Investment Partners LLC owned 0.14% of DexCom worth $5,817,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. Stephens Investment Management Group LLC lifted its stake in shares of DexCom by 409.8% during the third quarter. Stephens Investment Management Group LLC now owns 192,324 shares of the medical device company’s stock valued at $9,409,000 after buying an additional 154,596 shares during the period. Banque Pictet & Cie SA lifted its stake in shares of DexCom by 240.6% during the third quarter. Banque Pictet & Cie SA now owns 101,830 shares of the medical device company’s stock valued at $4,982,000 after buying an additional 71,930 shares during the period. Quantum Capital Management lifted its stake in shares of DexCom by 16.2% during the third quarter. Quantum Capital Management now owns 74,989 shares of the medical device company’s stock valued at $3,669,000 after buying an additional 10,443 shares during the period. Marble Harbor Investment Counsel LLC lifted its stake in shares of DexCom by 36.5% during the third quarter. Marble Harbor Investment Counsel LLC now owns 37,940 shares of the medical device company’s stock valued at $1,856,000 after buying an additional 10,150 shares during the period. Finally, Quantbot Technologies LP lifted its stake in shares of DexCom by 62.3% during the third quarter. Quantbot Technologies LP now owns 22,485 shares of the medical device company’s stock valued at $1,100,000 after buying an additional 8,630 shares during the period.

COPYRIGHT VIOLATION NOTICE: This story was published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this story on another publication, it was copied illegally and reposted in violation of US and international copyright and trademark law. The correct version of this story can be accessed at https://theolympiareport.com/2017/11/21/dexcom-inc-dxcm-position-boosted-by-granite-investment-partners-llc.html.

In related news, EVP Andrew K. Balo sold 3,244 shares of the firm’s stock in a transaction on Monday, September 11th. The shares were sold at an average price of $72.27, for a total transaction of $234,443.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Steven Robert Pacelli sold 1,450 shares of the firm’s stock in a transaction on Monday, September 25th. The shares were sold at an average price of $69.81, for a total transaction of $101,224.50. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 16,964 shares of company stock valued at $1,111,779. Company insiders own 1.70% of the company’s stock.

DXCM has been the topic of several recent analyst reports. Northland Securities downgraded shares of DexCom from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $85.00 to $60.00 in a research note on Thursday, September 28th. Wedbush reaffirmed a “buy” rating and set a $76.00 price target on shares of DexCom in a research note on Wednesday, October 4th. Zacks Investment Research downgraded shares of DexCom from a “hold” rating to a “sell” rating in a research note on Tuesday, October 24th. Robert W. Baird reaffirmed a “hold” rating and set a $79.00 price target on shares of DexCom in a research note on Sunday, September 10th. Finally, TheStreet downgraded shares of DexCom from a “c-” rating to a “d+” rating in a research note on Wednesday, October 25th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $70.69.

DexCom, Inc. (NASDAQ DXCM) traded up $0.65 on Tuesday, reaching $54.66. 1,227,600 shares of the company were exchanged, compared to its average volume of 1,431,208. DexCom, Inc. has a 1-year low of $42.62 and a 1-year high of $88.80. The company has a quick ratio of 5.50, a current ratio of 5.86 and a debt-to-equity ratio of 0.84.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.